Compare AngloGold Ashanti Limited (AU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Viatris Inc — how do they compare? AngloGold Ashanti Limited trades at $97.75 (market cap $49.28B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: AngloGold Ashanti Limited is far larger — about 2.6× Viatris Inc's market cap, and AngloGold Ashanti Limited pays the higher dividend (4.64%). Which is the better fit depends on your goals.
| AU | VTRS | |
|---|---|---|
Market Cap | $49.28B | $18.69B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $17.86 |
52-Week Low | $52.15 | $9.49 |
Enterprise Value | $48.29B | $30.80B |
Dividend Yield | 4.64% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $97.89, up 0.66% with strong bullish momentum from moving averages. The stock shows robust fundamentals with 32.19% net income margin and 46.5% ROE, supported by rising gold prices and production growth. Recent Q2 2026 earnings beat expectations with $727 million free cash flow, while the company maintains a $2 billion buyback program. Technical indicators show overbought conditions with RSI at 79.27, but institutional interest remains strong with multiple recent position increases.
Outlook remains positive with analyst consensus target of $120.33 (23% upside) and 64% buy ratings. Key catalysts include H2 production growth and shareholder returns, though risks include gold price volatility and operational challenges. The stock trades at reasonable valuations (P/E 13.06, EV/EBITDA 7.58) with improving balance sheet strength (debt-to-asset ratio declining to 15.59%).
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
